NASDAQ:IBRX

Immunitybio Stock Insider Trading

Healthcare > Biotechnology

Buy IBRX

*Your capital is at risk

$7.32

+0.100 (+1.39%)

At Close: Jun 23, 2026

ImmunityBio Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -19.61. In total, the insiders bought 13.97M and sold 1.31M IBRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-19.61
● Buy	13.97M shares
● Sell	1.31M shares
69% Buy Activity Moderate Negative Correlation
Sell Signal Medium Confidence Feb 23, 2026 Analysis Breakdown: Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Selecky Christobel Director	Director	65 600 Value: $475.6K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Cohen Cheryl Director	Director	65 600 Value: $475.6K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Clark Wesley Director	Director	65 600 Value: $475.6K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Maxwell Linda Director	Director	65 600 Value: $475.6K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Wendel Bruce Director	Director	65 600 Value: $475.6K
Jun 09, 2026 Buy	Stock Option (right to buy) A-Award	Blaszyk Michael D Director	Director	65 600 Value: $475.6K
Jun 04, 2026 Sell	Common Stock S-Sale	Simon Barry J. Director	Director	23 033 Value: $165.3K
Mar 31, 2026 Buy	Common Stock C-Conversion	Soon-shiong Patrick See Remarks	Officer	4 606 596 Value: $25.0M
Mar 31, 2026 Sell	Second Amended and Restated Convertible Promissory Note C-Conversion	Soon-shiong Patrick See Remarks	Officer	0 Value: $0
Feb 24, 2026 Sell	Common Stock S-Sale	Simon Barry J. Director	Director	75 000 Value: $900.8K
Feb 23, 2026 Buy	Stock Option (right to buy) M-Exempt	Selecky Christobel Director	Director	25 000 Value: $74.5K
Feb 23, 2026 Buy	Common Stock M-Exempt	Selecky Christobel Director	Director	25 000 Value: $74.5K
Feb 23, 2026 Sell	Common Stock S-Sale	Selecky Christobel Director	Director	25 000 Value: $250.0K
Feb 23, 2026 Sell	Common Stock S-Sale	Simon Barry J. Director	Director	165 000 Value: $1.69M
Feb 22, 2026 Sell	Common Stock F-InKind	Simon Barry J. Director	Director	6 026 Value: $52.4K
Feb 22, 2026 Buy	Common Stock M-Exempt	Simon Barry J. Director	Director	15 243 Value: $111.6K
Feb 22, 2026 Buy	Common Stock M-Exempt	Adcock Richard CEO & President	CEO / President	152 439 Value: $1.12M
Feb 22, 2026 Buy	Restricted Stock Units M-Exempt	Lauer Regan J Chief Accounting Officer	Officer	4 065 Value: $29.8K
Feb 22, 2026 Sell	Common Stock F-InKind	Lauer Regan J Chief Accounting Officer	Officer	1 673 Value: $14.6K
Feb 22, 2026 Buy	Common Stock M-Exempt	Lauer Regan J Chief Accounting Officer	Officer	4 065 Value: $29.8K
Feb 22, 2026 Buy	Restricted Stock Units M-Exempt	Soon-shiong Patrick See Remarks	Officer	114 329 Value: $836.9K
Feb 22, 2026 Sell	Common Stock F-InKind	Soon-shiong Patrick See Remarks	Officer	58 170 Value: $506.1K
Feb 22, 2026 Buy	Common Stock M-Exempt	Sachs David C. Chief Financial Officer	C-Suite Officer	40 650 Value: $297.6K
Feb 22, 2026 Sell	Common Stock F-InKind	Sachs David C. Chief Financial Officer	C-Suite Officer	20 682 Value: $179.9K
Feb 22, 2026 Buy	Restricted Stock Units M-Exempt	Sachs David C. Chief Financial Officer	C-Suite Officer	40 650 Value: $297.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMMUNITYBIO, INC.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of...

Read Full Profile Here